Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Belshe

Infectious Disease Saint Louis, MO Medical Doctor

NPI 1881700219 CMS profile 311928

3691 Rutger St, Suite 100, Saint Louis, MO 63110

Open in the dashboard

General payments

$381,600

181 records reported · program years 2019–2025

Research payments

$5,850

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Belshe of Saint Louis, MO is reported in the CMS Open Payments database as having received $381,600 across 181 general payments and $5,850 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,538 15
2024 General $36,185 17
2024 Research $5,850 1
2023 General $27,255 13
2022 General $67,845 28
2021 General $77,791 21
2020 General $77,432 37
2019 General $69,554 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Belshe
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Robert Belshe were reported at $25,538. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Robert Belshe Infectious Disease median Middle half National median
2019 $69,554 $190 $60–$862 $163
2020 $77,432 $124 $32–$606 $114
2021 $77,791 $148 $38–$905 $132
2022 $67,845 $166 $50–$834 $149
2023 $27,255 $171 $57–$787 $160
2024 $36,185 $176 $52–$752 $164
2025 $25,538 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $179,025 58 payments
  2. GlaxoSmithKline, LLC. $89,424 26 payments
  3. Sanofi Pasteur Inc. $76,210 72 payments
  4. Merck Sharp & Dohme Corporation $23,995 22 payments
  5. Dermira, Inc. $9,947 2 payments
  6. AstraZeneca Pharmaceuticals LP $3,000 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $325,698 113 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,720 17 payments
  3. Travel and Lodging $5,985 32 payments
  4. Food and Beverage $1,197 19 payments
Products named General payments · program years 2019–2025
  1. COMIRNATY Vaccines $46,113 19 payments
  2. FLUZONE HIGH-DOSE Vaccines $35,174 42 payments
  3. FLUBLOK QUADRIVALENT $30,101 35 payments
  4. FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Vaccines $20,673 25 payments
  5. FLUZONE HIGH-DOSE Vaccines $20,673 25 payments
  6. COMIRNATY Vaccines $12,950 3 payments
  7. QBREXZA $9,947 2 payments
  8. FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Vaccines $5,040 2 payments
  9. ENFLONSIA $1,110 2 payments
  10. NO PRODUCT DISCUSSED $241 3 payments
  11. Other $287 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $5,850 1 payment

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record